[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Kan WH, Hsu JT, Ba ZF, Schwacha MG, Chen J, Choudhry MA, Bland KI, Chaudry IH: p38 MAPK-dependent eNOS upregulation is critical for 17beta-estradiol-mediated cardioprotection following trauma-hemorrhage. Am J Physiol Heart Circ Physiol; 2008 Jun;294(6):H2627-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To study this, male Sprague-Dawley rats underwent soft-tissue trauma (midline laparatomy) and hemorrhagic shock (mean blood pressure 35-40 mmHg for 90 min), followed by fluid resuscitation.
  • Animals were pretreated with specific p38 MAPK inhibitor SB-203580 (SB; 2 mg/kg), and nonselective NO synthase inhibitor NG-nitro-l-arginine methyl ester (l-NAME; 30 mg/kg) 30 min before vehicle (cyclodextrin) or E2 (100 microg/kg) treatment, followed by resuscitation, and were killed 2 h thereafter.
  • E2 administration following trauma-hemorrhage increased cardiac p38 MAPK activity, eNOS expression and phosphorylation at Ser(1177), and nitrate/nitrite levels in plasma and heart tissues; these were associated with normalized cardiac performance, which was reversed by SB administration.
  • Administration of E2 following trauma-hemorrhage attenuated cardiac tissue injury markers, myeloperoxidase activity, and nitrotyrosine level, which were reversed by treatment with SB and l-NAME.
  • The salutary effects of E2 on cardiac functions and tissue protection following trauma-hemorrhage are mediated, in part, through activation of p38 MAPK and subsequent eNOS expression and phosphorylation.
  • [MeSH-major] Cardiotonic Agents / pharmacology. Estradiol / pharmacology. Heart Diseases / prevention & control. Mitogen-Activated Protein Kinase 11 / metabolism. Myocardium / enzymology. Shock, Hemorrhagic / drug therapy
  • [MeSH-minor] Abdomen / surgery. Animals. Calmodulin / metabolism. Caveolin 1 / metabolism. Chemokine CXCL1 / metabolism. Chemokine CXCL2 / metabolism. Disease Models, Animal. Enzyme Activation. Enzyme Inhibitors / pharmacology. Imidazoles / pharmacology. Intercellular Adhesion Molecule-1 / metabolism. Interleukin-6 / metabolism. Male. NG-Nitroarginine Methyl Ester / pharmacology. Nitrates / metabolism. Nitric Oxide Synthase Type II / antagonists & inhibitors. Nitric Oxide Synthase Type II / metabolism. Nitric Oxide Synthase Type III. Nitrites / metabolism. Peroxidase / metabolism. Phosphorylation. Pyridines / pharmacology. Rats. Rats, Sprague-Dawley. Tumor Necrosis Factor-alpha / metabolism. Tyrosine / analogs & derivatives. Tyrosine / metabolism. Up-Regulation. Ventricular Function / drug effects

  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408136.001).
  • [ISSN] 0363-6135
  • [Journal-full-title] American journal of physiology. Heart and circulatory physiology
  • [ISO-abbreviation] Am. J. Physiol. Heart Circ. Physiol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / R37 GM39519
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calmodulin; 0 / Cardiotonic Agents; 0 / Cav1 protein, rat; 0 / Caveolin 1; 0 / Chemokine CXCL1; 0 / Chemokine CXCL2; 0 / Cxcl1 protein, rat; 0 / Cxcl2 protein, rat; 0 / Enzyme Inhibitors; 0 / Imidazoles; 0 / Interleukin-6; 0 / Nitrates; 0 / Nitrites; 0 / Pyridines; 0 / SB 203580; 0 / Tumor Necrosis Factor-alpha; 126547-89-5 / Intercellular Adhesion Molecule-1; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; 4TI98Z838E / Estradiol; EC 1.11.1.7 / Peroxidase; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nitric Oxide Synthase Type III; EC 1.14.13.39 / Nos3 protein, rat; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 11; V55S2QJN2X / NG-Nitroarginine Methyl Ester
  •  go-up   go-down


2. Khorgami Z, Nasiri S, Rezakhanlu F, Sodagari N: Malignant schwannoma of anterior abdominal wall: report of a case. J Clin Med Res; 2009 Oct;1(4):233-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant peripheral nerve sheath tumors (MPNST) represent approximately 10% of all soft tissue sarcomas and it is found in 4% of patients with neurofibromatosis 1.
  • She presented with a painful mass in the right upper quadrant of her abdomen.
  • The tumor location was in the abdominal wall in explorative laparatomy and malignant schwannoma was diagnosed in pathologic assessment.
  • The tumor recurred in 3 months and computed tomography showed two masses in the right side of abdominopelvic cavity.
  • In spite of administering chemotherapy after second surgery,the tumor recurred and magnetic resonance imaging finding showed a huge heterogeneously enhancing mass with adhesion to the inner side of the abdominal wall.
  • Tumor location and rapid recurrence was unique in our patient.
  • KEYWORDS: Malignant peripheral nerve sheath tumor; Malignant schwannoma; Abdominal wall.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22461875.001).
  • [ISSN] 1918-3003
  • [Journal-full-title] Journal of clinical medicine research
  • [ISO-abbreviation] J Clin Med Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3299187
  •  go-up   go-down


3. Adibi A, Barikbin R, Koleini N, Farghadani M, Mougouei K, Farshidfar F: Solitary epidural brain metastasis of a peripheral neuroepithelioma (a primitive neuroectodermal tumor): a case report. J Radiol Case Rep; 2008;2(1):16-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary epidural brain metastasis of a peripheral neuroepithelioma (a primitive neuroectodermal tumor): a case report.
  • The patient was a known case of cervical soft tissue primitive neuroectodermal tumor (PNET) who has undergone surgery and radiotherapy 4 years ago.
  • After diagnosis the patient has undergone chemotherapy and radiotherapy.
  • He remained symptom free, and also follow up CT scans of the brain, chest, and abdomen were normal after two years post surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22470583.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303233
  •  go-up   go-down


Advertisement
4. Engin G, Asoglu O, Kapran Y, Mert G: A gastrointestinal stromal tumor with mesenteric and retroperitoneal invasion. World J Surg Oncol; 2007;5:121
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A gastrointestinal stromal tumor with mesenteric and retroperitoneal invasion.
  • In this report we present a case of gastrointestinal stromal tumors with mesenteric and retroperitoneal invasion, describe and discuss its computed tomography findings.
  • During physical examination, significant distention and multiple palpable tumor masses were identified on the abdomen.
  • Abdominal computed tomography showed multiple, well-defined, soft tissue masses with homogenous and heterogeneous pattern, in the mesenteric and retroperitoneal areas.
  • Unlike specific features of gastrointestinal stromal tumor, renal obstruction and atypical central calcification without chemotherapy that has not been yet described were seen in this case.
  • Computed tomography did not reveal liver metastases and/or the lymph nodes with pathological size.
  • Ultrasonography-guided true-cut biopsy was made, histopathologic and immunohistochemical analyses demonstrated stromal tumor which, C-KIT (+).
  • CONCLUSION: When intraabdominal, multiple, large (>5 cm), well-circumscribed, homogenous or heterogeneous mass lesions without ascites, omental caking and lymph nodes metastases were seen, gastrointestinal stromal tumors should be considered in the differential diagnosis.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Neoplasm Invasiveness / pathology. Peritoneal Neoplasms / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Laparotomy. Male. Mesentery. Middle Aged. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Control. 2005 Apr;12(2):111-5 [15855894.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):566-78 [15781488.001]
  • [Cites] Pol J Pathol. 2005;56(2):51-61 [16092666.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):310-4 [16414236.001]
  • [Cites] Radiographics. 2006 Mar-Apr;26(2):481-95 [16549611.001]
  • [Cites] World J Gastroenterol. 2007 Apr 14;13(14):2077-82 [17465451.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):211-22 [10680889.001]
  • [Cites] Mod Pathol. 2000 May;13(5):577-85 [10824931.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1134-42 [11048809.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • [Cites] Gastrointest Endosc. 2002 Jan;55(1):37-43 [11756912.001]
  • [Cites] Radiology. 2003 Feb;226(2):527-32 [12563150.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):703-8 [12760289.001]
  • [Cites] Eur Radiol. 2003 Jul;13(7):1669-78 [12835984.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1178-86 [14515284.001]
  • [Cites] World J Gastroenterol. 2004 Aug 15;10(16):2417-8 [15285033.001]
  • [Cites] Eur Radiol. 2004 Oct;14(10):1926-9 [15300393.001]
  • [Cites] Hum Pathol. 1992 Jul;23(7):762-7 [1612575.001]
  • [Cites] Am J Surg Pathol. 1993 Jun;17(6):588-94 [8333557.001]
  • [Cites] Mod Pathol. 1997 Mar;10(3):200-9 [9071727.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):407-16 [9130987.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):82-7 [9888707.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):937-45 [10435564.001]
  • [Cites] AJR Am J Roentgenol. 2005 Mar;184(3):803-11 [15728601.001]
  • [Cites] Eur Radiol. 2005 Jul;15(7):1407-14 [15761716.001]
  • (PMID = 17958889.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2164961
  •  go-up   go-down


5. King JJ, Fayssoux RS, Lackman RD, Ogilvie CM: Early outcomes of soft tissue sarcomas presenting with metastases and treated with chemotherapy. Am J Clin Oncol; 2009 Jun;32(3):308-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early outcomes of soft tissue sarcomas presenting with metastases and treated with chemotherapy.
  • OBJECTIVES: The purpose of this study is to describe outcomes for patients with metastatic soft tissue sarcoma treated with chemotherapy.
  • METHODS: We retrospectively reviewed the records of 383 soft tissue sarcoma patients treated at our institution from 1997 to 2006.
  • Thirty-five patients met the inclusion criteria-metastatic disease on presentation; primary tumor outside the abdomen; treatment with chemotherapy; and minimum follow-up of 3 months.
  • Treatments were individualized and determined by a multidisciplinary oncology team.
  • Twenty-nine patients (83%) presented with pulmonary metastasis, 6 with bone metastases (17%), 4 with regional node metastases (11%), and 4 with soft tissue metastases (11%).
  • The 10 patients with complete resection or complete chemotherapy response of all detectable lesions had longer mean survival (34 months) than the 25 patients who had partial/no resection or response (20 months) (P = 0.02).
  • CONCLUSIONS: Soft tissue sarcoma patients presenting with metastatic disease have a low survival rate, but complete eradication of tumor correlated with longer survival.
  • Longer-term studies especially those tracking the outcome of complete responders and those completely resected will help determine the efficacy of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Neoplasms / secondary. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433963.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Wessalowski R, Schneider DT, Mils O, Hannen M, Calaminus G, Engelbrecht V, Pape H, Willers R, Engert J, Harms D, Göbel U: An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Padiatr; 2003 Nov-Dec;215(6):303-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors.
  • BACKGROUND: Elevated temperatures of 40 - 44 degrees C increase the actions of various anticancer drugs including N-lost derivatives, cytotoxic antibiotics and platinum analoga.
  • In clinical usage thermochemotherapy (TCH) should facilitate surgical resection and ameliorate local tumor control.
  • Among these, 24 patients had extracranial non-testicular germ cell tumors and 15 patients soft tissue or chondrosarcomas.
  • INDICATION: locoregional relapse (n = 29) or unresectable tumor after neoadjuvant chemotherapy (n = 10).
  • Among these two groups, there were ten patients with poor response or progressive disease under primary or relapse chemotherapy.
  • Tumor site: pelvis (30), abdomen (4), head and neck (2), proximal leg (2) and lumbar spine (1).
  • TCH was followed by surgical tumor resection in 28/39 patients and/or radiotherapy in 13/39 patients.
  • CONCLUSION: TCH shows substantial therapeutic efficacy and facilitates complete tumor resection in 14 out of 28 operated patients.
  • Multimodal treatment including TCH, surgical resection and/or radiotherapy leads to sustained remission in the majority of patients with locoregional tumor recurrence.
  • The therapeutic effect is most pronounced, if TCH is administered at first relapse.
  • Therefore, a more valid assessment of treatment efficacy can only be made by a matched-pair comparison in cooperation with the clinical registers.
  • [MeSH-major] Abdominal Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Chondrosarcoma / therapy. Cisplatin / therapeutic use. Etoposide / therapeutic use. Germinoma / therapy. Head and Neck Neoplasms / therapy. Hyperthermia, Induced. Ifosfamide / therapeutic use. Lumbar Vertebrae. Pelvic Neoplasms / therapy. Sarcoma / therapy. Soft Tissue Neoplasms / therapy. Spinal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Combined Modality Therapy. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Infant. Karnofsky Performance Status. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Time Factors. Treatment Outcome


7. Puri A, Chandrasekharam VV, Agarwala S, Gupta AK, Bhatnagar V: Pediatric extragonadal germ cell tumor of the scalp. J Pediatr Surg; 2001 Oct;36(10):1602-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric extragonadal germ cell tumor of the scalp.
  • Extragonadal germ cell tumor of the scalp is exceedingly rare.
  • The authors report the case of a 1(1/2)-year-old boy with extragonadal germ cell tumor over the occipital region.
  • Examination of the chest, abdomen, and gonads was normal.
  • Computed tomography scan of the head showed a large, well-defined, lobulated, heterogeneously enhancing soft tissue mass lesion in the occipital region.
  • The child was started on chemotherapy and received 4 cycles of cisplatin, etoposide, and bleomycin (PEB).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Germinoma / drug therapy. Head and Neck Neoplasms / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Infant. Male

  • Genetic Alliance. consumer health - Extragonadal Germ Cell Tumor.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11584421.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Valdivia Gómez GG, Soto Guerrero MT, Cedillo de la Cruz MI: Extra-skeletal Ewing's sarcoma resembling acute abdomen. Case report. Cir Cir; 2010 Mar-Apr;78(2):159-62
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra-skeletal Ewing's sarcoma resembling acute abdomen. Case report.
  • BACKGROUND: Extraosseous Ewing's sarcoma is a rare tumor of neuroectodermal origin.
  • It presents mainly in the soft tissue of the extremities and thorax.
  • CLINICAL CASE: We present the case of a male who arrived at the emergency room with acute abdomen, leucocytosis and imaging techniques (abdominal ultrasound and computed tomography) suggestive of complicated diverticular disease.
  • Intraoperative findings were an unsuspected tumor (20 x 15 x 15 cm).
  • Treatment consisted of extirpation of the tumor, separating it from the adjacent viscera and followed by chemotherapy based on epirubicin, cyclophosphamide and vincristine for six cycles.
  • Because the control abdominal CT demonstrated tumor activity in the retroperitoneum adjacent to the ascending colon and cecum, further resection was decided upon.
  • CONCLUSIONS: In a review of the literature, no previous reports of extraosseous Ewing's sarcoma were found presenting as acute abdomen.
  • Due to the rarity of this tumor, only case reports or series have been found in the literature without randomized or comparative studies.
  • Surgery was the cornerstone of treatment, without reports of preoperative chemotherapy.
  • If the patient's condition permits, percutaneous needle biopsy is mandatory to obtain optimum treatment as well as to improve prognosis.
  • [MeSH-major] Abdomen, Acute / diagnosis. Retroperitoneal Neoplasms / diagnosis. Sarcoma, Ewing / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20478118.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


9. Salvi PF, Moles N, Gazzetti M, Lombardi A, Puzzovio A, Mongardini M: [Desmoid tumor of rectus muscle of abdomen in a woman of childbearing age: what can we do?]. G Chir; 2003 Nov-Dec;24(11-12):413-7
Genetic Alliance. consumer health - Desmoid Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Desmoid tumor of rectus muscle of abdomen in a woman of childbearing age: what can we do?].
  • The desmoid tumor (DT) is a soft tissue neoplasm most frequently localized in the anterior abdominal wall typically in females of childbearing age.
  • Because its particular incidence in women who had recently been pregnant, it was correlated with delivery's trauma stimulating proliferation of muscolo-aponeurotic tissues.
  • Complete surgical resection is the recommended treatment approach to prevent recurrence.
  • Many authors emphasize the role of radiotherapy in regression of DT and in controlling local recurrence in patient who had incomplete resection.
  • Many others emphasize the role of chemotherapy or antiestrogenic compounds, even though tumour does not express estrogen receptors.
  • DT, otherwise, is neoplasm with high rates of recurrence after surgery but it never develops distant metastases, so that function and structure-sparing surgery may be a reasonable choice in young women when possible without leaving macroscopic residual disease.
  • In women of childbearing age, even after non radical histological DT primary resection, adjunctive radiotherapy, chemotherapy or antiestrogen therapy could be avoided and clinical observation alone may be considered.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15018410.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Kara IO, Gonlusen G, Sahin B, Ergin M, Erdogan S: A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma. Is there any role in disease process? Saudi Med J; 2005 Aug;26(8):1190-6
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma. Is there any role in disease process?
  • OBJECTIVE: Within soft-tissue sarcoma, primitive neuroectodermal tumors have been shown to cover a wide spectrum of small round cell sarcomas, including Ewing's sarcomas (ES) and primitive neuroectodermal tumors (PNET).
  • The role of the stem cell factor/kit pathway has been investigated in different human tumors especially in chronic myelocytic leukemia and gastrointestinal stromal tumor and an autocrine loop has been assumed in small cell lung carcinoma, and recently in ES and PNET.
  • METHODS: We thoroughly searched the archives of the Department of Pathology, Faculty of Medicine, Cukurova University Turkey, between 2000 and 2004; and found 14 ES and 14 PNET paraffin embedded tissues.
  • We carried out the detection of the c-kit expression by immunohistochemical staining.
  • The main localization of the disease was lower extremity (32.1%), and others were as follows: head and neck 25%, thorax and abdomen 14.3%, pelvic and upper extremity 7.1% (11 were localized skeletal and 17 were extraskeletal).
  • According to treatment modalities, 10 were treated with surgery alone, 11 with surgery and chemotherapy, and 7 with surgery, radiation therapy and also with chemotherapy.
  • The primary tumor was lower than 5 cm in its dimension in 21 patients.
  • While in 5 patients, tumor was more than 5 cm but did not exceed 10 cm, it was >10 cm in 2 patients.
  • There was no significant correlation between c-kit expression and gender, localization, metastatic status, treatment modalities and tumor.
  • CONCLUSION: We suggest that therapy with tyrosine kinase inhibitor for PNET and ES patients may be an alternative in addition to standard therapy modalities, especially in patients non-responsive to standard therapy.

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127511.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


11. Krawczuk-Rybak M, Leszczyńska E, Zelazowska-Rutkowska B, Wysocka J: [Ovarian function in young women after anticancer treatment in childhood]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1028-34
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian function in young women after anticancer treatment in childhood].
  • AIM: We investigated pituitary-ovarian function in young women after treatment for different cancers in prepubertal and pubertal periods, with or without radiotherapy of infradiaphragmatic areas.
  • PATIENTS AND METHODS: We analyzed the values of follicle-stimulating hormone (FSH) luteinizing hormone (LH), estradiol (E2), inhibin B and anti-müllerian hormone (AMH) in the group of 28 young women aged 18.6 +/- 4.7 years, who had been treated for Hodgkin's Lymphoma HL (n=16), nephroblastoma (n=7), soft tissue sarcoma (n=4), neuroblastoma (n=1).
  • RESULTS: In the whole group the mean levels of FSH, LH and E2 did not differ from the control group, but in the subgroup irradiated infradiaphragmatically FSH concentration was higher than in the control group (8.06+/-3.28 vs 5.8+/-2.03 mIU/ml) p=0.042, particularly after HL treatment (8.53+/-3.25 mIU/ml), p=0.045.
  • Mean AMH levels were significantly lower in the whole analyzed group than in the control one (22.8+/-16.3 vs 29.4+/-13.2 pmol/l) p=0.036, particularly in the subgroup irradiated for abdomen (17.2+/-14.9 pmol/l) p=0.025.
  • Inhibin B was also lower in the whole group, (27.98+/-17.8 ng/l vs 47.9+/-26.4 ng/l) p=0.035, and in the subgroup with non-irradiated abdomen 25.9+/-14.1 ng/l, p=0.01.
  • We did not observe the influence of age at treatment (prepubertal vs pubertal period) on the values of analyzed hormones.
  • CONCLUSIONS: In young women after anti-cancer treatment, with normal menstrual cycles, the signs of ovarian dysfunction and diminished ovarian reserve are observed.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Ovarian Diseases / etiology. Ovary / drug effects. Ovary / radiation effects. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Anti-Mullerian Hormone / blood. Biomarkers / blood. Child. Estrogens / blood. Female. Follicle Stimulating Hormone / blood. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Humans. Inhibins / blood. Kidney Neoplasms / drug therapy. Kidney Neoplasms / radiotherapy. Neuroblastoma / drug therapy. Neuroblastoma / radiotherapy. Sarcoma / drug therapy. Sarcoma / radiotherapy. Wilms Tumor / drug therapy. Wilms Tumor / radiotherapy

  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531821.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Estrogens; 0 / inhibin B; 57285-09-3 / Inhibins; 80497-65-0 / Anti-Mullerian Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


12. Siva Prasad G, Chacko KN, Antony D, Lionel G, Kekre NS, Gopalakrishnan G: Bladder-sparing surgery in locally advanced nonurological pelvic malignancy. Urol Int; 2006;77(1):18-21
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Often a dilemma exists between cystectomy and a bladder-sparing procedure.
  • 10 had locally advanced colorectal malignancy, 3 with soft tissue masses of the lateral pelvic wall, 1 had ovarian malignancy and the other had residual mass following radiotherapy and chemotherapy of cancer cervix.
  • Urine examination and ultrasonography was not helpful in suggesting bladder involvement, unlike CT scan of abdomen and pelvis.
  • Palliative transurethral resection was done in 1 patient with tumor infiltration at the bladder neck and prostate.
  • Preoperative CT scan or MRI can predict lower urinary tract involvement and help in decision-making by both surgeon and patient.
  • The ultimate decision for bladder sparing is based on intraoperative findings.
  • [MeSH-major] Colorectal Neoplasms / surgery. Ovarian Neoplasms / surgery. Soft Tissue Neoplasms / surgery. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825810.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


13. Gelderblom H, Hogendoorn PC, van der Graaf WT, Verweij J: [Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor]. Ned Tijdschr Geneeskd; 2003 Oct 18;147(42):2051-5
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor].
  • [Transliterated title] Imatinib, een specifieke tyrosinekinaseremmer, voor de behandeling van patiënten met een gastro-intestinale stromaceltumor.
  • GISTs are a heterogeneous group of mesenchymal tumours, mainly localised in the abdomen.
  • Immunohistochemical staining using antibodies directed towards the c-kit protein on the cell surface, is a useful tool in the often difficult differential diagnosis of GISTs from other mesenchymal tumours.
  • The correct diagnosis of GISTs is crucial for the new treatment option with imatinib, the tyrosine-kinase inhibitor specifically targeted against KIT.
  • As a result of the short period of time between the drug's experimental introduction and actual registration, many unanswered questions about its use for the treatment of GISTs remain.
  • It is therefore recommended that patients with these rare tumours are referred to a centre with experience in the diagnosis and treatment of these soft-tissue sarcomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use
  • [MeSH-minor] Benzamides. Combined Modality Therapy. Diagnosis, Differential. Humans. Imatinib Mesylate. Proto-Oncogene Proteins c-kit / genetics. Stromal Cells. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2003 Oct 18;147(42):2041-3 [14606347.001]
  • (PMID = 14606351.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 21
  •  go-up   go-down


14. Macapinlac M, Elrafei T, Cunningham I, Horowitz M, Fauzia P, Mbaoma R, Jayabalan D, Mani S: Dermatofibrosarcoma protuberans: Neoadjuvant therapy with imatinib mesylate and use of plasma PDGF-B levels to monitor clinical response. J Clin Oncol; 2004 Jul 15;22(14_suppl):9049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatofibrosarcoma protuberans: Neoadjuvant therapy with imatinib mesylate and use of plasma PDGF-B levels to monitor clinical response.
  • : 9049 Background: Dermatofibrosarcoma protuberance (DFSP) is a rare soft tissue sarcoma; most cases show t(17:22) resulting in a COL1A1-PDGF-B fusion protein.
  • Imatinib mesylate, a known inhibitor of the PDGF receptor tyrosine kinase, has produced responses in some patients with chemotherapy-resistant locally advanced or metastatic DFSP.
  • Wide surgical excision of the tumor is still the accepted treatment despite local recurrence rate of 20-50% in completely resected patients.
  • Chest and abdomen CT showed no metastasis and PET scan showed uptake in facial lesions only.
  • CONCLUSIONS: This case shows the potential use of imatinib as neoadjuvant treatment in DFSP, and the potential value of measuring serial PDGF-B levels as a novel tumor marker not only in DFSP but perhaps in all tumors that depend on the PDGF-B pathway.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014126.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Petković M, Zamolo G, Muhvić D, Coklo M, Stifter S, Antulov R: The first report of extraosseous Ewing's sarcoma in the rectovaginal septum. Tumori; 2002 Jul-Aug;88(4):345-6
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ewing's sarcoma is a highly malignant neoplasm of bone, which usually occurs during childhood.
  • METHODS: A 45-year-old woman presented to us with a six-month history of pain in the lower abdomen during intercourse.
  • The mass had a size of 9 x 6 cm, a soft tissue consistency, was partially movable and the patient felt the pain during palpation.
  • Computed tomography (CT) showed an inhomogeneous expansive mass in the rectovaginal septum measuring 8.7 x 6.1 cm, without any signs of rectum or bladder invasion.
  • At laparotomy the process was judged inoperable and only biopsy of the tumor mass was carried out.
  • Histology showed a neoplasm with small, round to oval cells with scarce cytoplasm.
  • The patient was treated with chemotherapy followed by whole-pelvis external beam radiation and intracavitary brachytherapy.
  • RESULTS: A residual mass measuring 3.5 x 2.5 cm was visible on a control CT scan 18 months after treatment; however, the patient was feeling well and refused surgery to remove the residual mass.
  • [MeSH-major] Rectal Neoplasms / therapy. Sarcoma, Ewing / therapy. Vaginal Neoplasms / therapy

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12400989.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Salemis NS, Gourgiotis S, Tsiambas E, Panagiotopoulos N, Karameris A, Tsohataridis E: Primary intra-abdominal malignant fibrous histiocytoma: a highly aggressive tumor. J Gastrointest Cancer; 2010 Dec;41(4):238-42
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intra-abdominal malignant fibrous histiocytoma: a highly aggressive tumor.
  • BACKGROUND AND PURPOSE: Malignant fibrous histiocytoma (MFH) is the most common soft-tissue sarcoma of late adult life occurring predominantly in the extremities.
  • Computed tomography (CT) scan demonstrated a mass in the right iliac fossa.
  • RESULTS: On exploratory laparotomy, a tumor was found in the right iliac fossa attached to the parietal lateral peritoneum without any evidence of invasion into the adjacent structures.
  • Complete excision of the tumor with clear margins was performed.
  • One month after surgery, while on adjuvant chemotherapy, the patient was readmitted with dyspnea and a slightly palpable mass in the area of the previous radical resection.
  • CT scan revealed local tumor recurrence along with multiple pulmonary metastatic deposits.
  • Unfortunately, despite treatment, the patient died of progressive disease 5 weeks later.
  • Early detection and complete surgical excision with clear margins is the treatment of choice.
  • In some cases, however, the tumor can exhibit a highly aggressive clinical course despite radical surgery and adjuvant therapy.
  • [MeSH-major] Abdomen / pathology. Histiocytoma, Malignant Fibrous / secondary. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):983-94 [8600111.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):499-505 [1845950.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • [Cites] Cancer. 1992 Apr 15;69(8):2098-103 [1311983.001]
  • [Cites] World J Gastroenterol. 2007 Feb 28;13(8):1299-302 [17451221.001]
  • [Cites] Gastrointest Radiol. 1988 Oct;13(4):299-305 [2844619.001]
  • [Cites] Exp Hematol. 1993 Sep;21(10):1342-52 [7689482.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Surg Today. 2003;33(10 ):794-6 [14513333.001]
  • [Cites] Surg Today. 2002;32(12):1091-5 [12541030.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] World J Gastroenterol. 2007 Dec 21;13(47):6441-3 [18081238.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):16-22 [11823689.001]
  • [Cites] Clin Imaging. 1998 Nov-Dec;22(6):408-13 [9876909.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Dig Surg. 1999;16(5):425-30 [10567806.001]
  • [Cites] Int Semin Surg Oncol. 2006 Jun 22;3:15 [16792809.001]
  • [Cites] Int J Gastrointest Cancer. 2005;36(2):105-12 [16648661.001]
  • (PMID = 20419356.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Li L, Cen S, Huang F: [Clinical research on 11 cases of epithelioid sarcoma]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Dec;21(12):1315-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical features, diagnosis, and treatment of patients with localized epithelioid sarcoma (ES).
  • The ES was located in the upper extremity in 7 patients,lower extremity in 3, and abdomen in 1.
  • Tumor <2 cm was seen in 7 patients, 2-5 cm in 1, and >5 cm in 3.
  • Seven patients underwent an expanding resection surgery, and the tumors with the surrounding normal tissues 3 cm above were removed.
  • All the patients underwent routine radiotherapy and chemotherapy after operation.
  • They did not have a further surgical treatment.
  • CONCLUSION: An early expanding resection surgery combined with postoperative chemotherapy and radiotherapy is the therapy of choice for treating ES.
  • [MeSH-major] Sarcoma / diagnosis. Sarcoma / surgery. Surgical Flaps. Upper Extremity / surgery
  • [MeSH-minor] Adolescent. Adult. Amputation. Bone Transplantation. Female. Hand / pathology. Hand / surgery. Humans. Lower Extremity / pathology. Lower Extremity / surgery. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Soft Tissue Injuries / surgery. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277674.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Dilek TU, Dilek S, Pata O, Tataroglu C, Tok E: Malignant fibrous histiocytoma of the ovary: a case report. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:352-6
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant fibrous histiocytoma is the most common type of soft tissue sarcoma in adults.
  • She was referred for adjuvant chemotherapy to our center with the diagnosis of storiform-pleomorphic malignant fibrous histiocytoma.
  • A left adnexal mass was detected by computed tomography of the lower abdomen.
  • Resection of all macroscopic disease is independently associated with improved disease-specific survival, and adjuvant chemotherapy for nonmyxoid variants could be acceptable alternatives if the surgical margins are tumor free.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Female. Humans. Reoperation

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515621.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Atmatzidis KS, Pavlidis TE, Galanis IN, Papaziogas BT, Papaziogas TB: Malignant fibrous histiocytoma of the abdominal cavity: report of a case. Surg Today; 2003;33(10):794-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant fibrous histiocytoma (MFH) is a soft-tissue sarcoma originating from fibroblast cells, characterized by a high rate of metastasis or recurrence.
  • This tumor rarely develops in the gastrointestinal tract, with no more than 30 cases described in the literature.
  • A computed tomography (CT) scan of the abdomen revealed multiple solid tumors in the peritoneal cavity.
  • Histopathological findings indicated a stromal tumor consisting of spindle cells, and immunohistochemical examination of the resected specimens established the definite diagnosis of a pleomorphic MFH.
  • The patient had an uneventful postoperative course and was given adjuvant chemotherapy.
  • We review the clinical picture of this tumor in the abdominal cavity, and discuss its diagnosis, pathogenesis, and treatment.
  • [MeSH-minor] Female. Humans. Intestine, Small. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14513333.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vande Berg B, Lecouvet FE: Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate; 2005 Oct 1;65(2):178-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases.
  • Here, we assessed the value of MRI of the axial skeleton (AS-MRI) as a single step technique to quantify bone metastases and measure tumor response.
  • METHODS: AS-MRI was performed in 38 patients before receiving chemotherapy for metastatic HRPCa, in addition to PSA, computed tomography of the thorax, abdomen, and pelvis [CT-TAP]; and Tc-99m bone scintigraphy.
  • A second AS-MRI was performed in 20 patients who completed 6 months of chemotherapy.
  • Evaluation of tumor response was performed using RECIST.
  • RESULTS: Only 11 patients (29%) had RECIST measurable metastases in soft-tissues or lymph nodes on baseline CT-TAP.
  • Transposing RECIST on AS-MRI in 20 patients who completed 6 months of treatment, allows the accurate estimation of complete response (n = 2), partial response (n = 2), stable disease (n = 5), or tumor progression (n = 11), as it is done using CT-TAP in soft tissue solid metastases.
  • CONCLUSIONS: MRI of axial skeleton enables precise measurement and follow-up of bone metastases as it is for other soft-tissue metastasis.
  • [MeSH-minor] Endpoint Determination. Humans. Male. Prospective Studies. Treatment Outcome


21. Lal DR, Su WT, Wolden SL, Loh KC, Modak S, La Quaglia MP: Results of multimodal treatment for desmoplastic small round cell tumors. J Pediatr Surg; 2005 Jan;40(1):251-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of multimodal treatment for desmoplastic small round cell tumors.
  • We examined the effects of multimodal therapy including induction chemotherapy, aggressive surgical debulking, and external beam radiotherapy on patients with DSRCT.
  • Data were collected on patient demographics, presenting symptoms, tumor location and extent, treatment regimen, and overall survival.
  • RESULTS: A majority of patients were male (91%), Caucasian (85%), and with a median age of 19 (7-58) years old at diagnosis.
  • In 63 patients (96%), the primary tumor was located in the abdomen or pelvis.
  • Thirty-three (50%) had positive lymph nodes and 27 (41%) had distant parenchymal metastases at diagnosis.
  • Twenty-nine of these patients (44%) underwent induction chemotherapy (P6), surgical debulking, and radiotherapy.
  • Three-year survival was 55% in those receiving chemotherapy, surgery, and radiotherapy vs 27% when all 3 modalities were not used (P < .02).
  • Gross tumor resection was highly significant in prolonging overall survival; 3-year survival was 58% in patients treated with gross tumor resection compared to no survivors past 3 years in the nonresection cohort (P < .00001).
  • CONCLUSIONS: Multimodal therapy results in improved survival in patients with DSRCT.
  • [MeSH-major] Sarcoma, Small Cell / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Abdominal Neoplasms / therapy. Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Pelvic Neoplasms / pathology. Pelvic Neoplasms / surgery. Pelvic Neoplasms / therapy. Radiotherapy. Surgical Procedures, Operative. Survival Analysis. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery. Testicular Neoplasms / therapy. Thoracic Neoplasms / pathology. Thoracic Neoplasms / surgery. Thoracic Neoplasms / therapy. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868593.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Paikos P, Papathanassiou M, Stefanaki K, Fotopoulou M, Grigorios S, Tzortzatou F: Malignant ectomesenchymoma of the orbit in a child: Case report and review of the literature. Surv Ophthalmol; 2002 Jul-Aug;47(4):368-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant ectomesenchymoma is a rare soft tissue tumor of childhood composed of both mesenchymal and neuroectodermal elements.
  • Reported sites of origin are head and neck, abdomen, perineum, scrotum, and extremities.
  • The clinical picture of the tumor, radiological findings, and its histopathologic and immunohistochemical characteristics are described.
  • The patient was successfully treated with combined surgical resection and chemotherapy.
  • [MeSH-minor] Child. Combined Modality Therapy. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12161212.001).
  • [ISSN] 0039-6257
  • [Journal-full-title] Survey of ophthalmology
  • [ISO-abbreviation] Surv Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


23. Cecchetto G, Carretto E, Bisogno G, Dall'Igna P, Ferrari A, Scarzello G, Donfrancesco A, Alaggio R, Indolfi P, Carli M: Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee. Pediatr Blood Cancer; 2008 Nov;51(5):593-7
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee.
  • PROCEDURE: We analyzed data from 39 patients (age: 0.5-194 months, median 52) who were enrolled between 1988 and 2005 in 2 consecutive Italian Studies, RMS 88 and RMS 96.
  • All achieved a complete resection of the residual tumor after neoadjuvant chemotherapy; 27 did not receive any other local treatment: pelvic 8, extremities 6, head-neck-non-parameningeal 5, orbit 1, genito-urinary-bladder-prostate 3, trunk 2, abdomen 1, vagina 1; 12 were given RT (32-45 Gy), 5 before and 7 after the operation: genito-urinary-bladder-prostate 3, pelvic 3, abdominal 1, extremities 1, head-neck-parameningeal 1, head-neck-non-parameningeal 1, vagina 1, orbit 1.
  • All received postoperative chemotherapy.
  • Without RT: 16/27 maintained the first complete remission, however 1/16 died due to a second tumor; 8 suffered from local relapse (4 pelvic, 1 orbit, 1 vagina, 1 head-neck-non-parameningeal, 1 abdomen) and 3 of them died, 3 showed a metastatic recurrence (2 extremities, 1 pelvic) and 1 died.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Child, Preschool. Clinical Trials as Topic. Combined Modality Therapy. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Radiotherapy, Adjuvant. Sarcoma

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18668515.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Paulino AC, Mayr NA, Simon JH, Buatti JM: Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity. Int J Radiat Oncol Biol Phys; 2002 Mar 15;52(4):1025-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity.
  • Primary tumor was located in the adrenal gland in 26 (49%), abdomen/nonadrenal in 14 (26%), thorax in 9 (17%), neck in 2 (4%), and pelvis in 2 (4%).
  • All patients, except 11 with Stage 4S and 4 with Stage 4, had resection of the primary tumor.
  • Postoperative doses ranged from 15 to 25 Gy whereas preoperative doses ranged from 12 to 31 Gy using a median fraction size of 1.5 Gy.
  • Chemotherapy was employed in 22 of 53 patients (42%) with the most common agents being cyclophosphamide in 22 and doxorubicin in 11.
  • RESULTS: Tumor control: The 5-year overall and freedom from progression rates were 79 +/- 9% and 81 +/- 11%; the locoregional control rate was 88 +/- 9%.
  • Five of 6 infants <6 months of age and 1 of 7 >/=6 months developed musculoskeletal toxicity.
  • Musculoskeletal effects were seen in 6 RT patients and included bony hypoplasia in 6, scoliosis in 5, soft tissue hypoplasia in 3, slipped capital femoral epiphysis in 2, kyphosis in 1, and osteochondroma in 1.
  • Three required orthopedic intervention, all receiving >/=20 Gy.
  • One child developed bowel obstruction at 21 months and another developed a leiomyosarcoma in the treatment field 34 years after RT.
  • [MeSH-minor] Abdominal Neoplasms / mortality. Abdominal Neoplasms / pathology. Abdominal Neoplasms / radiotherapy. Combined Modality Therapy. Disease Progression. Female. Humans. Infant. Infant, Newborn. Lymphatic Metastasis. Male. Musculoskeletal Diseases / etiology. Neoplasm Staging. Pelvic Neoplasms / mortality. Pelvic Neoplasms / pathology. Pelvic Neoplasms / radiotherapy. Radiation Injuries / complications. Survival Rate. Thoracic Neoplasms / mortality. Thoracic Neoplasms / pathology. Thoracic Neoplasms / radiotherapy. Treatment Failure

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1575; author reply 1575 [12459387.001]
  • (PMID = 11958898.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Baz W, El-Soueidi R, Nakhl F, Aoun N, Chin N, Dhar M: Desmoplastic small round-cell tumor: an adult with previous exposure to agent orange. Jpn J Clin Oncol; 2010 Jun;40(6):593-5
Hazardous Substances Data Bank. 2,4-D .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic small round-cell tumor: an adult with previous exposure to agent orange.
  • Desmoplastic small round-cell tumor is an uncommon, highly aggressive tumor with a predilection for pediatric age groups and young adults.
  • Although Agent Orange has been associated with soft-tissue sarcoma, an association with desmoplastic small round-cell tumor has not been reported.
  • On physical examination, the abdomen was distended and tense.
  • Computed tomography scan of the chest, abdomen and pelvis demonstrated extensive mediastinal and retroperitoneal adenopathy, diffuse omental masses and extensive pleural, intra-abdominal and pelvic ascites.
  • Omental core needle biopsy was consistent with desmoplastic small round-cell tumor based on morphology and immunohistochemistry.
  • He responded poorly to chemotherapy with high-dose cyclophosphamide, doxorubicin and vincristine and died 5 months after presentation secondary to neutropenic sepsis despite G-CSF support and antibiotics.

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • Hazardous Substances Data Bank. 2,4,5-T .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20382635.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Defoliants, Chemical; 2577AQ9262 / 2,4-Dichlorophenoxyacetic Acid; 39277-47-9 / Agent Orange; 9Q963S4YMX / 2,4,5-Trichlorophenoxyacetic Acid; DO80M48B6O / Tetrachlorodibenzodioxin
  •  go-up   go-down


26. Olgun N, Kansoy S, Aksoylar S, Cetingul N, Vergin C, Oniz H, Sarialioglu F, Kantar M, Uysal K, Tuncyurek M, Kargi A, Aktas S, Bayol U, Karaca I, Arikan A, Balik E, Aktug T, Elmas N, Kovanlikaya A, Kinay M, Anacak Y, Degirmenci B, Burak Z: Experience of the Izmir Pediatric Oncology Group on Neuroblastoma: IPOG-NBL-92 Protocol. Pediatr Hematol Oncol; 2003 Apr-May;20(3):211-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IPOG-NBL-92 protocol modified from German Pediatric Oncology (GPO)-NB-90 protocol was applied: Patients in stage 1 received only surgery, while surgery plus 4 chemotherapy courses (cisplatin, vincristine, ifosfamide) were given in stage 2 and surgery plus 6 chemotherapy courses (cisplatin, vincristine, ifosfamide, epirubicin, cyclophosphamide) were given in stages 3 and 4 patients.
  • In patients who were kept in complete remission (CR), a maintenance therapy of one year was applied.
  • Radiotherapy was given to the primary site following induction chemotherapy plus surgery in stages 3 and 4 patients with partial remission (PR).
  • Primary tumor site was abdomen in 88% of cases.
  • The median follow-up time for survivors was 33 (17-102) months.
  • Univariate analysis established that the age, stage, primary tumor site, and high LDH and NSE levels conferred a significant difference.
  • However, more effective treatments suitable to Turkey's social and economic conditions are urgently needed for children over 1 year of age with advanced neuroblastoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neuroblastoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Child. Child, Preschool. Clinical Trials as Topic. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Male. Multicenter Studies as Topic. Neoplasm Staging. Survival Analysis. Survival Rate. Treatment Outcome. Turkey

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12637217.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Zhao J, Han B, Shen T, Zhao Y, Wang T, Liu Y, Fang K, Zhong D, Ling Q: Primary cutaneous diffuse large B-cell lymphoma (leg type) after renal allograft: case report and review of the literature. Int J Hematol; 2009 Jan;89(1):113-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous diffuse large B-cell lymphoma (leg type) after renal allograft: case report and review of the literature.
  • We report a case of a 58-year-old man who presented with a rapidly growing proliferative lesion on the left lower limb, clinically resembling a soft tissue sarcoma 3 years after renal allograft.
  • There was no evidence of systemic involvement on bone marrow needle aspiration and computed tomography (CT) scans of the chest and abdomen.
  • The lesion turned out to be primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL LT), as defined in the recent World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification of cutaneous lymphomas by skin biopsy.
  • Immunosuppression reduction, chemotherapy with CHOP regimen and local radiotherapy induced complete remission of the tumor.
  • [MeSH-minor] Humans. Leg / pathology. Male. Middle Aged. Neoplasm Invasiveness. Remission Induction / methods. Skin Neoplasms / etiology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3602-10 [11504742.001]
  • [Cites] Pediatr Transplant. 2005 Oct;9(5):622-6 [16176420.001]
  • [Cites] J Cardiovasc Pharmacol Ther. 2006 Mar;11(1):77-83 [16703222.001]
  • [Cites] Arch Dermatol. 2004 Sep;140(9):1140-6 [15381556.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Clin Transplant. 2005 Oct;19(5):668-73 [16146560.001]
  • [Cites] Br J Dermatol. 2005 Nov;153(5):874-80 [16225594.001]
  • [Cites] Transplant Proc. 2006 Mar;38(2):641-5 [16549195.001]
  • [Cites] Transplant Proc. 2007 May;39(4):1071-3 [17524894.001]
  • [Cites] Clin Transplant. 2005 Jun;19(3):327-34 [15877793.001]
  • [Cites] Am J Transplant. 2006 Nov;6(11):2735-42 [17049061.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):574-80 [11939732.001]
  • [Cites] Arch Dermatol. 2007 Sep;143(9):1144-50 [17875875.001]
  • [Cites] Transplantation. 2005 Sep 15;80(5):595-9 [16177631.001]
  • [Cites] Transplant Proc. 2006 Oct;38(8):2448-50 [17097963.001]
  • [Cites] Blood. 2002 Feb 1;99(3):800-5 [11806979.001]
  • [Cites] J Cutan Pathol. 2005 Nov;32(10):647-74 [16293178.001]
  • [Cites] Transplantation. 2006 Mar 27;81(6):888-95 [16570013.001]
  • [Cites] Arch Dermatol. 2005 Sep;141(9):1139-45 [16172311.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1065-70 [16957512.001]
  • [Cites] Transplantation. 2005 Jul 27;80(2):193-7 [16041263.001]
  • (PMID = 19109733.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down






Advertisement